[Edaily Reporter Park Jeong-soo] #NeoImmuneTech announced on the 10th that it has decided to conduct a 1.5 billion won rights offering to secure operating funds (funds for acquiring all rights to Endari in North America). The capital increase will be conducted via a third-party allotment, with the allottee being Emmaus Life Sciences of the United States. The new shares consist of 683,960 common shares, and the issue price is 2,220 won (discount rate: -10%). The new shares are scheduled to be listed on the 6th of next month.
Disclosure Plus
NeoImmunetech Decides on 1.5 Billion Won Third-Party Allotment Capital Increase
Park Jung-Soo
2026-06-10 16:50:02
Economy
Corporation
IT·Science
Economy
[Exclusive] Funds Frozen, Yet 120 Billion Won Embezzled… First Investigation into KOK Coin
E-Daily signed a Memorandum of Understanding (MOU) on the 5th of last month with Core Security, a leading domestic blockchain security firm, for the “Crypto X-File Project: Reporting Digital Asset Fra…
Corporation
INNOSIMULATION CO., LTD. Partners with Japan's FORUM8 to Target the Driving Simulator Market
INNOSIMULATION CO., LTD.(274400) is partnering with FORUM8, a Japanese engineering VR and 3D software company, to expand into the Japanese driving simulator market.
INNOSIMULATION CO., LTD. ann…
IT·Science
'Qing Dynasty Stone Lion Statues' from China Now in VR… Naver Labs Creates Digital Replica for Gansong Art Museum
Naver Labs, the research and development division of Naver (NAVER(035420)), has recreated the exhibition spaces and key collections of the Gansong Art Museum in virtual reality (VR). This allows visit…
